|Mitsubishi Tanabe Pharma Corporation|| |
The money will be used to advance Cytochroma's portfolio of vitamin D-based therapeutics into mid- and late-stage clinical trials.
|Tetraphase Pharmaceuticals |
|Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures|| |
Tetraphase will use the funding to support the advancement of several antibiotic drug candidates.
|Celator Pharmaceuticals |
|Domain Associates, Ventures West, Quaker BioVentures, TL Ventures, GrowthWorks Capital, and BDC Capital|| |
The money will be used to finance mid-stage studies of CPX-351 for acute myeloid leukemia.
|Sierra Neuropharmaceuticals |
|HealthCare Ventures, Morgenthaler Ventures, and Sequel Venture Partners|| |
Sierra, which is based in Colorado, plans to formulate drugs that can be delivered directly to the fluid around the brain in order to provide more effective treatment for severe CNS diseases like epilepsy, depression and schizophrenia.
Cytochroma gets $45M in third round